Proof of Concept for Lenvatinib and Everolimus Prior to Cytoreductive Nephrectomy in Eligible Patients With Locally Advanced and Metastatic Renal Cell Carcinoma (RCC)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 04 Dec 2018 Planned number of patients changed from 13 to 15, Trial focus changed due to addition of Safety endpoint for primary outcome.
- 16 Oct 2018 Planned End Date changed from 1 Nov 2019 to 30 Apr 2021.
- 16 Oct 2018 Planned primary completion date changed from 1 Nov 2019 to 30 Apr 2021.